๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Telix Pharmaceuticals Limited (ASX:TLX)
Australia flag Australia ยท Delayed Price ยท Currency is AUD
13.22
+0.01 (0.08%)
Nov 19, 2026, 4:10 PM AEDT
โ† View all transcripts

UBS Global Biopharma Conference 2026

Nov 17, 2026

Summary

Imaging generated ~ $1bn in 2026 revenue and >$400m in cash, while prostate imaging retained >40% market share. BYPASS, product approvals and the ITM transaction underpin a busy 2027 catalyst calendar and plans for six approved products.

David Dai
Biotech Analyst, UBS

Absolutely. Great. Okay. Thanks everyone for joining. We have a fireside chat with Telix Pharmaceuticals. My name is David Dai. I am one of the Biotech Analysts here at UBS. With us here, we have Christian Behrenbruch, who is Group Chief Executive Officer for Telix Pharmaceuticals Group. I also have Richard Valeix, who is the Chief Executive Officer of the Therapeutics business. It is great to have both executives here at the podium here. Maybe a quick background for those of you who are not familiar with the story. Telix is a very interesting biopharmaceutical company. They have two business segments, actually, a precision medicine business where they are looking at diagnostics for prostate cancer, but also you have a therapeutics business. We will dive into both segments of the story today.

Maybe just from a high level, Chris, if you can just help us understand a little more about the Telix story overall. Tell us a little more about those two segments of your business.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Sure. Well, first of all, thanks for the opportunity. Essentially, when we started the company, the vision was that we would bootstrap a commercial business using imaging as a low-hanging fruit. We were one of the first companies to get into PSMA imaging. It has been a very successful growth story. It has been successful clinically. It has had a big impact on patient outcomes. This year, that business for us does roughly $1 billion in revenue. We continue to see lots of growth in that business. We are not a diagnostics company. We have always been a therapeutics company, but we saw the diagnostics business as a kind of an ATM machine for the company.

This year, we threw off over $400 million of cash that we used then to finance our R&D, our infrastructure, which is sort of technically a third part of our business for the manufacturing and supply chain piece, and that ties into some of our recent M&A activity. The second part that you note is that we probably have, and I am pleased to be joined by Richard. Richard leads our therapeutics business. We probably have the largest portfolio of molecules in the industry, from preclinical to three phase III trials, that are actively recruiting in prostate, renal, and glioblastoma. We are really excited about that. A lot of data catalysts upcoming. We are a self-financed company, and I think that over the next 12 months, we have a whole ton of approval and clinical catalysts that are really exciting.

David Dai
Biotech Analyst, UBS

Got it. Great. Maybe just dive into some of the big commercial products here. Maybe just help us understand a little bit about some of the key commercial products they have right now. You have your prostate cancer diagnostic, imaging diagnostic, like Illuccix, Gozellix. Tell us a little more about that. Also, as you're thinking about the evolution of the business, how has that evolved over the past, let's say, two, three years? Now you're going from a diagnostics business to a therapeutics business.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Yeah. Well, we were second to market with PSMA, but we think that we've really established a leadership momentum. We have two products that serve primarily the U.S. market, although we are commercially active in 22 countries. Illuccix and Gozellix have quite different clinical profiles. They have different distribution profiles. They're targeted at different segments, different payer segments. It's been quite a successful strategy for us, and it's enabled us to take about just over 40% market share, even coming to market second. We're really heading toe-to-toe with our competition. Our competition had a flat year. We did over 25% growth this year in our prostate business. I think it really shows that our multi-product strategy is working well. That comes from a very deep level of engagement with the urologist.

I think one of the things that we've done very deliberately is to build referral physician and disease focus area depth. We don't try to scattergun a whole lot of different areas of the clinic. We try to focus on a few disease areas and a few specialty areas that we think we can do really well in, and urology is one of those. Following the prostate franchise, we have our renal cancer products or Zircaix, which is just about to get refiled. It's in publishing right now for our BLA resubmission, which will happen before the end of the year. That will be then a third product targeted at the urologist. We actually have R&D activity in bladder cancer and so forth coming in behind. Really, the goal is to be that sort of one-stop shop in radiopharma, diagnostically and therapeutically eventually.

We have two phase III trials with the kind of companion therapeutics to those. That's really a concentrated focus. Our third product approval, which we got this year, is Pixclara, which is an imaging agent for glioblastoma. Unsurprisingly, we also have the phase III therapeutic asset, which is generating really interesting data. They target the same mechanism, the same transporter in glioblastoma. Pixclara very much paves the way for that therapeutic business in brain cancer as well.

David Dai
Biotech Analyst, UBS

Got it. That's really good. You recently acquired a company called ITM. Tell us a little more about the strategic rationale of that acquisition, and how should investors think about the potential benefits to supply, security, as well as speed? How are you also coming on the product called ITM-11? How it complements your pipeline?

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Yeah. We haven't acquired them yet. We've agreed to acquire them. The close will hopefully take place before the end of the year. We are on track to meet the closing conditions of the transaction. I think it's fair to say both companies are really enthusiastic about this merger. We're actually kind of sister companies. We were born out of the same stable of innovators and shareholders. It makes a lot of sense over time that the companies finally come together. The impetus for us merging with ITM, and it really is more of a merger in terms of the way that the deal's structured and the sort of expectations and the way in which we'll bring the management teams together. I think there were three things that were very compelling. They have the only really global terabecquerel scales lutetium supply chain.

We have a very large number of assets that are going to be reliant on scale-up lutetium, and so we felt that there are 42 assets that require lutetium that are in mid or late-stage development. At some point in time, we don't want to be in a queue. So we felt that, as we have done with all of the isotopes that we work with, security of supply, it's not even just a consideration, it's absolutely critical in radiopharma. The second aspect of the transaction is that they have a joint venture with CNL called Actineer, and we have been working with actinium with some partners. They are also making great strides. I think actinium's going to be an important isotope going forward.

We have a number of assets that we are developing with actinium in mind, so that was compelling to have that self-supply and access to a lot of radium. The third thing, as you mentioned, was ITM-11. So, Richard, and maybe I'll ask Richard to comment additionally, but our original trajectory was really towards the back end of 2028 that we were going to make that transition to a therapeutics company with our GBM product. ITM-11, which is a, I would say, describe it sort of as a bio-better of Illuccix, brings that therapeutic event horizon forward by about 18 months. It's a clinically differentiated product. It has a very different label scope. It has a lot of logistical advantages over both the incumbent and the emerging generics. It's got a very long shelf life. It's got a lot of distribution flexibility.

We're excited to be distributing that product through our nuclear pharmacy network and through a key partner nuclear pharmacy network. It's a very natural drop-in fit and enables us really to go toe-to-toe with some of the emerging competition to Novartis in this space. I think NET's still important. I think there's a lot more still to be done in NET. NET is a very diverse disease. We like some of the potential label expansions that will come from ITM-11, so I think it's got a lot of potential. I don't know if you want to add anything since you had a lot of historical experience with Illuccix in the past.

Richard Valeix
CEO of Therapeutics, Telix Pharmaceuticals

Yeah, exactly, as you mentioned. NET for me, it's really my baby because I did develop Illuccix for many years, so I know what the radiopharma compound can bring to this disease. The association between first lutetium and actinium can be a way to explore the future. Also, the association with the existing treatment in combo therapy. There's many, many ways that we can develop that. ITM has rightly started also initiating the clinical trial in pulmonary with a NET neuroendocrine part in the disease, so that will make sense. We saw already physicians which have tested this product in this disease. Now we have to transform that with a marketing authorization.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Yeah. If I could just quickly add to that, with the Regeneron transaction, we had the aspiration to go into a new disease focus area, which I guess you would call loosely kind of thoracic oncology. Having that first potential label expansion, and that will read out next year around the lung NETs, is a kind of an interesting first venture in that as a commercial franchise. There's a lot of strategy and a lot of synergies between the ITM business and things that we have been both working on for many years, but also things that are in the future landscape of the business.

David Dai
Biotech Analyst, UBS

It sounds like a very interesting acquisition where you are completing all the existing manufacturing as well as the pipeline actually complements with your existing strategies extremely well.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Yeah.

David Dai
Biotech Analyst, UBS

Let's dive into this and especially the commercial story a little bit more.

This is top of mind for most investors, especially you guys, as you mentioned, Chris, that you've seen 25% growth throughout with your precision medicine business, probably Illuccix and Gozellix so far. Tell us what drove that, and then think about, just say next year or two, how do you envision the sustainable growth, especially on double digits that we're looking at here, and go on from there? Tell us understanding more about that business.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

No, I think it's a key question. It's a question that's on the forefront of investors at the moment. We had a pretty flat Q3, which wasn't a surprise to us. We planned for it. We reiterated our guidance for the year. As the market matures with the current labels that we have, with the current indication landscape we have, it's understandable. Q4, and we disclosed it, our exit into Q4 has been really strong, so we expect to see that continued growth. We think that there is an endogenous 5%-7% growth in PSMA still, and then with the BYPASS indication, I can't tell you how excited I am about this. This is a phase III trial that we've now enrolled. We're in the observation period. The data should read out sometime towards the back end of Q1 or maybe early Q2 next year.

This has the potential to add almost a million scans to the TAM in the U.S. We have agreed with the FDA on a distinct NDA pathway because it's not really medically adjacent to the current indications, and it's a fast-track designated program, so we are hopeful that the agency will review it quickly, and we expect to pursue a rolling submission for that because of the fast track. So I think it's a program that has a high degree of certainty. It should have been called the PRIMARY3 study, really. PRIMARY and PRIMARY2 have been published, and sometimes companies forget that we build on the shoulders of giants, and we had the investigators behind the PRIMARY studies really contribute and define what the study needed to be.

We actually tried to take PRIMARY2 to the agency for approval, but it had certain design elements that were more of a hypothesis assessing study than a kind of suitable for a label expansion. We decided to bite the bullet and make the investment to run BYPASS, and I think it will be a step change again in the size of the prostate cancer market. There is so much clinical excitement about this trial. Yeah, I think we really have a strong leadership position that will contribute to the growth. The other thing that we have is a super compelling strategy around targeting urological oncology and urology practices, and there we leverage our RLS business. We are building portable and microsatellite pharmacies embedded into urology practices, which are becoming key stakeholders of nuclear medicine, much like cardiology used to be, or is. We have seen urology say, "You know what?

We are going to continue to take charge of the patient." We are seeing a huge appetite to buy scanners and to build true theranostic capacity, and so we want to service that directly. We want to be that partner of choice, and we are having a lot of success with that. We think that in three years' time, that 25% of PSMA scans will be done directly under urology supervision, and so we want to facilitate that market and be that just turnkey, easy button solution for urology. I do not have any doubt that we can continue to grow, and then when Zircaix gets approved, hopefully towards the end of the first half of next year, that is our sort of current expectation on timing, that will give us another really powerful talk track for the urologist that will further embed us into the urology practice.

It will give us more opportunities to cross-sell. I see lots of dynamism in our PSMA business going forward.

David Dai
Biotech Analyst, UBS

Awesome. Got it. Yeah, actually, I just wanted to maybe dive into the BYPASS a little more because I do feel like that is a really interesting expansion strategy. Did you mention 1 million scans?

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Mm-hmm. 1 million.

David Dai
Biotech Analyst, UBS

1 million scans.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Yeah.

David Dai
Biotech Analyst, UBS

Help us understand more on that number. Where did that come from? Also, where do you see this unmet need, and with BYPASS, you can potentially move into a biopsy setting.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

That's right.

David Dai
Biotech Analyst, UBS

Where are physicians seeing the gap here?

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

There's 1 - 1.2 million basically template biopsies done in the U.S. every year. About 80% of those don't yield clinically actionable information. There's a huge morbidity and just patient and frankly practice inconvenience. It's one of those things where nobody really wants to do it. Urologists don't want to do it, patients don't want to do it. If nobody had to do it'd be great. It doesn't take away a revenue stream because there's the possibility of imaging to come in. From a patient outcome, patient convenience perspective, the idea of BYPASS is to have that PET scan combined with an MRI that allows you to decide whether you can eliminate a biopsy or have a single focal biopsy, like an image-guided biopsy to biopsy a particular area, or in the worst-case scenario, do that template biopsy.

Not only will it impact and triage and apply. We're not trying to eliminate biopsy. That's not the goal. That would be a terrible objective. The goal is to only use biopsy where it's absolutely necessary with the right risk classification. There's estimated to be around 200,000 - 300,000 men that just don't engage with the process at all. Not going to have. Don't want to know, don't want to have a needle biopsy anywhere near my nether regions. They just don't engage. Those are the men that tend to turn up with late-stage disease. If we can, from a compliance perspective, bring them into the fold, that has a huge economic consequence to the healthcare system. You start to add up those numbers, and there's no shortage of interest and desire. These patients love the idea.

KOLs love the idea. I have to tell you, it's the fastest clinical trial, and we recruited 300-odd patients who did it in five months. I've just never seen anything like it. People were like, "We have to do this." I think it's going to be a really good thing that the health economics make a lot of sense. Patients are going to be so much better off, and I do think that compliance, that patient compliance piece is really critical. Yeah.

David Dai
Biotech Analyst, UBS

Excellent. This is fantastic. Data will be back half of 1Q next year, and then you imagine or envision the regulatory process to be pretty fast, given the fact you already have a PRO 2 product that's approved in the same indication core.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Yeah, and also, I think the clinical data is relatively low risk, the way the trial's been designed. Then, I don't like to acknowledge it out loud, but we've had, like many radiopharma companies, we've had our ups and downs with CMC. The BYPASS trial builds on an established CMC package. So, I think that we've got a pretty clear run at it, barring anything unexpected coming out of the clinical trial. But it's a really well-thought-out study, and as I said, we are really building on the prior outcomes that have been well studied.

David Dai
Biotech Analyst, UBS

Great. Then just to maybe wrap up the commercial business before we move to the therapeutic, which I do want to spend some time on. Just on the two new products, right? One, Zircaix in urologic cancer, especially in kidney cancer. Where do we stand on the regulatory front? Also for Pixclara in early in its, right, in terms of brain imaging, what have you seen so far in terms of adoption?

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Yeah. Well, Zircaix has been very frustrating. We had an amendment to our CRL that we didn't ask for, that arrived in May with some extra manufacturing considerations that have turned out in hindsight with our discussions to the FDA to be not really applicable, but really caused us some delay, about six months of delay. I think that as our field, to put it politely, as our field matures, I think both industry and regulators are trying to get their head around a lot of new isotopes, a lot of new manufacturing considerations. It was the first time that a biologic-based PET agent had been put in front of the agency, and I think there was a steep learning curve on both sides. We've now had all the consultations with the FDA. There's no more data collection from the manufacturing side.

We've submitted all the 483 responses, so we're just now in publishing. It'll be, before the I keep saying imminently. There are four CMS entry points a year for reimbursement, so it gives us a quarter of latitude. For us, we're just making sure that we hit that kind of approximately mid-year CMS reimbursement entry point to be able to sort of have no gap between approval and submission. That's kind of what we're timing ourselves up against. Zircaix is going well. The package is a lot stronger. Pixclara, we've only had a couple of months of sales on it now. It gets reimbursement in January. It's not a hugely reimbursement-sensitive product, but reimbursement will help. We kept an expanded access program alive during the resubmission process.

We showed our customers, I know our clinician stakeholders, that we were really committed to their patients. So it's been a swift uptake. Pixclara has huge expansion capability, including the fact that we're currently running a phase III trial in mets from non-CNS primaries as well. That will significantly expand the scope. We did get a very broad label for Pixclara, so we think it has utility in very broad usage in glioblastoma management. I think you're going to see a pretty healthy growth in that business over the next couple of years.

David Dai
Biotech Analyst, UBS

How big do you think the Pixclara market opportunity is going to be in numbers terms?

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

In the U.S., the incidence of glio is 20,000-25,000 patients, but this is not a single time point scan. This is a multi-time point scan. We think it will get used. If you look at countries in Europe and Australia that currently use FET PET, typically a patient gets scanned 2x, 3x over the course of their disease journey. It's really useful to establish a baseline scan. Because our label is progressive or recurrent glioblastoma, there's a motivation to actually take data points as the patient exhibits changes. We think that it's a few hundred million dollar business opportunity. I think that the ASP that we have on that product, people were a bit surprised at in terms of, it's a healthy ASP that reflects the niche nature of the product. It's got a more bespoke manufacturing profile, some lower volume manufacturing.

I think that it's a good cost-benefit story, but it's also a good growth story for Telix. Then when you add in the CNS met opportunity, that can add another 120,000-150,000 scans to the story. I don't see any reason why we can't get Pixclara beyond a sort of half a billion dollar business opportunity. But really huge amount of benefit to patients. When we talk about Pixclara, we always say time is of the essence. Today you have to do multi-time point MRI scanning to see whether a patient is progressing. It takes several weeks to collect that data. Now with a single instantaneous time point, we can say, "Is this patient really progressing or is this a treatment-related change?" I think that's a real game changer for moving fast, acting swiftly with a GBM patient.

Richard Valeix
CEO of Therapeutics, Telix Pharmaceuticals

It paves the way for the therapeutic compound that-

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Well, thanks for chiming in. That's exactly right. Same target, patient selection. Pixclara is our patient selection tool for TLX101. It's firmly embedded in our clinical trials.

David Dai
Biotech Analyst, UBS

Great. I'd love to talk a little more about TLX101 in a bit, but maybe just switch over to the therapeutic business and focus on TLX591, which is your radiopharma product for prostate cancer. Where do you envision, Richard, TLX591 could fit into the current landscape for prostate cancer, given that there's Pluvicto and others in development? Where do you see it?

Richard Valeix
CEO of Therapeutics, Telix Pharmaceuticals

First, TLX591 is our lead asset. As you know, we are running the phase III trial currently. The characteristic of the TLX591 is extremely interesting because it is an antibody, and we can propose a treatment with two doses versus five or six for the peptide. We have an extremely low salivary gland uptake and kidney uptake, which confers some very good proprietary to the compound. I really believe that we position this compound in the right setting, which is the first and second line of mCRPC associated with the standard of care treatment. That is the request from the physicians when we were designing the clinical trial. They said, "We need to work with the existing treatment in place.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

To really layer it in. That is what is so nice about it. It just kind of slots right in very flexibly into treatment.

Richard Valeix
CEO of Therapeutics, Telix Pharmaceuticals

Exactly. For that, they needed a product with our characteristics. So, easy to manipulate, only two doses, with a good safety profile, so they can play with it. That is exactly what we are trying to demonstrate with our phase III trial.

David Dai
Biotech Analyst, UBS

How is the phase III trial going so far? What does enrollment look like? Any thoughts in terms of data updates?

Richard Valeix
CEO of Therapeutics, Telix Pharmaceuticals

We had an agreement with the FDA, a phase III trial with two parts. Part one was a kind of safety leading study that the FDA requested. We had to recruit 30 patients, 10, 10, according to the association of products that we wanted to have with the TLX591. This part is done. We disclosed the results in the first part of the year. Very good results, by the way. We move smoothly into part two, which is actively recruiting currently. The recruitment is moving very well. We have seven countries currently open across the world. U.S. is coming beginning of next year. I would say that currently we are very proud of this lead asset.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Yeah, it's doing great.

David Dai
Biotech Analyst, UBS

Great. There's another product for prostate cancer called TLX597, right?

Richard Valeix
CEO of Therapeutics, Telix Pharmaceuticals

Yeah.

David Dai
Biotech Analyst, UBS

Tell us a little bit more about that product, and how do you envision both TLX591 and TLX597 would be part of that strategy for prostate cancer?

Richard Valeix
CEO of Therapeutics, Telix Pharmaceuticals

Yeah. Because prostate cancer is a very complicated disease, as you know, from metastatic hormone-sensitive setting to the mCRPC settings, there's a complete different way to approach the disease. We wanted to co-position an antibody and a peptide. We developed for the TLX597, which is a peptide, and we tested it with an amazing result in terms of safety profile. First, we have demonstrated that in the first clinical trial, the uptake in the salivary gland and in the kidney are almost nothing, which is amazing. When you think how to co-position this product versus the TLX591, it's immediately in your mind, you think that you can position that in the early setting in the disease, in the hormone-sensitive setting space.

Because the patients will have to live for a long period of time, and we don't want to decrease their quality of life, and also keeping the opportunity to treat with other treatments during the disease pathway. We are currently running many clinical trials with this TLX597, which is our second asset. We will have results that will be disclosed next year from a clinical trial named OPTIMAL-PSMA, led by Louise Emmett in Australia. I really encourage you to be there when we will disclose this result at the ASCO next year. That will be very interesting.

David Dai
Biotech Analyst, UBS

Right. So, one for hormone-sensitive, which is TLX597, and then another for hormone-resistant, which is TLX591. So, two compound strategies for prostate cancer overall. Very exciting there. Then, moving on to TLX250 and TLX101, as you mentioned before. Tell us a little bit more about those two products. As you think about these two products in terms of fitting to the current treatment landscape for kidney cancer, TLX250, and also TLX101 for brain cancer, how do you envision the market opportunity is going to look like for these two products?

Richard Valeix
CEO of Therapeutics, Telix Pharmaceuticals

First, I have perhaps to replace. So, the TLX250 is an antibody named girentuximab. It's a fantastic target because it's not only expressed in renal cell carcinoma, which is our lead asset, where we want to go. Because as Chris said, we will have very soon a compound for diagnostic. So, it was legitimate to say that we will have a therapeutic compound also in renal cell carcinoma. But this target is also expressed in many other tumor types. So, I would say that it's really the first step for this compound. We run a phase III trial currently ongoing, named LUTEON. It's a phase II/III that we are running, and I'm extremely confident that the first results will reinforce the directions to lead to a therapeutic compound in renal cell carcinoma and open the door for the other oncology disease that we are targeting with this compound.

That is for the TLX250. Then we have in parallel the TLX101 compound, also in a phase III trial, the third one for the company in therapy, which is IPAX BrIGHT, where we, based on the very good results that we have from the compassionate use program, especially in Europe, where so many patients have been already treated in some countries, we really wanted to propose this phase III trial for the patients, and in order to target a registration as soon as possible. As you know, there is no real treatment that has been proposed to this type of patients during the last 20 years. We really wanted to speed up this recruitment, so we have an innovative treatment study design, I would say, with IPAX BrIGHT, that we are currently running across the world.

David Dai
Biotech Analyst, UBS

Got it. Great. Just for maybe one last question. I know we are actually out of time. For the next six to 12 months, Chris, what would you say is the key focus for investors to keep an eye on? What are some key catalysts we should be watching for?

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Yeah. Zircaix resubmission and approval. Clearly important. ITM submission and approval, clearly important. This will all happen in the next six months. ITM-11 resubmission is a condition of close of the transaction, so you should expect to see that and Zircaix kind of get resubmitted around the same time. The readout for BYPASS, maturation of data on part one for the ProstACT Global, I think that will generate quite a lot of interest. Then we have a bunch of clinical readouts over the course of the year across the rest of the programs. We also have two label expansions for ITM-11 that will read out next year in second and third line GEP-NET, and then also in lung NET, which is a really interesting and very novel indication.

I think, I mean, really, every year the company gets bigger and more exciting, and our revenue streams continue to grow very well. But I think 2027 is going to be the biggest year. We had a really very tough year of growth in 2025. 2026, we sort of fixed ourselves, made a lot of organizational changes, made a lot of leadership changes. We also get to bring on I mean, I will tell you the thing that I am most excited about from ITM is not just the great supply chain and the pipeline that is very complementary, but the talent, the people. We have a huge unmet need in this industry. We just need as many experts in radiopharma as we can.

I am super excited about adding around 800 more experts to the company, and I think 2027 is going to be just a monster year for the company. As I said in the outset, this time next year, we should have six approved products, a fully vertically integrated supply chain. I think we really don't have a peer in our industry. I think 2027 is a very exciting year for the company.

David Dai
Biotech Analyst, UBS

Great. Well, looking forward to 2027 and looking forward to a lot of updates from you guys.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

That was going to be a great year. Thank you for your time.

David Dai
Biotech Analyst, UBS

Thank you so much, Chris. I really appreciate it.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Thank you.

David Dai
Biotech Analyst, UBS

Thank you, Richard.

Christian Behrenbruch
Group CEO, Telix Pharmaceuticals

Thank you.

David Dai
Biotech Analyst, UBS

Thank you, everyone.